Clinical Study Of Liujunzi Decoction In Preventing And Tratment Of CINV In Young Patients With Primary Bone Tumor Of Spleen And Stomach Qi Deficiency Syndr

Objective To investigate the effectiveness of the combined application of Liujunzi Decoction and"palonosetron hydrochloride+dexamethasone+metoclopramide hydrochloride"in the chemotherapy process for the prevention and treatment of nausea and vomiting in chemotherapy in order to treat gastrosplenic deficiency type of primary malignant bone tumors in young patients.Methods Seventy-four patients(75 patients,one patient with exfoliation)who underwent chemotherapy for primary malignant bone tumors from March 2018 to March 2019 were randomly divided into treatment group(37 cases)and observation group(37 cases).The high-sputum chemotherapy regimen(including AP+I,AP+2M+I,MAID,VAC+IE)which was defined in the NCCN Oncology Clinical Practice Guidelines-Vomiting was tested to confirm the baseline between the two groups.The observation group used the combination of"palonosetron hydrochloride+dexamethasone+metoclopramide hydrochloride"as the main program before the first group of chemotherapy drugs,and then before each chemotherapy drug.Then repeat the combination of“dexamethasone+metoclopramide hydrochloride”for4 days.Based on the observation group,the treatment group was given the addition and subtraction of Liujunzi Decoction by TCM,starting from 3 days before the chemotherapy,once per day,BID in the morning and evening,a total of 7 doses.The clinical effects were evaluated using the Standards of Clinical Clinical Conference of Cancer in Europe and Traditional TCM Oncology via scoring standards.The Adverse events and myelosuppression reaction during chemotherapy were recorded.Results For patients in the treatment group and the observation group in regard of gender(x~2=2.680,P=0.160),age(t=0.119,P=0.906),culture level(x~2=0.218,P=0.816),tumor type(x~2=1.014,P=0.602),metastasis(x~2=0.066,P=1.000),tumor site(x~2=0.569,P=0.752)and chemotherapy regimen(x~2=1.418,P=0.341),the baseline was consistent between the two groups.The incidence of chemotherapy-related nausea and vomiting in the treatment group and the observation group were 86.49%and 97.30%,respectively,and the difference was not statistically significant(x~2=2.902,P=0.088).The treatment group and the observation group were based on The Standard of the European Conference on Clinical Cancer(x~2=3.430,P=0.330)or The Digestive System Symptom Index(x~2=5.676,P=0.225).There was no significant difference in the distribution,but the efficacy of the treatment group was slightly better than that of the observation group(x~2=5.506,P=0.019).There was no significant difference in myelosuppression between the two groups(x~2=0.505,P=0.918).The adverse reactions were tolerated in both the treatment group and the observation group during the test.These adverse reactions mainly include:lethargy,fatigue,constipation,headache,rash,chest tightness and cough.There was no significant difference in the overall incidence of adverse reactions(x~2=0.107,P=0.744).Conclusion Liujunzi decoction combined with"palonosetron hydrochloride+dexamethasone+metoclopramide hydrochloride"regimen has no effect on the adverse events and the course of chemotherapy in young patients with bone tumors during the period of chemotherapy,and has high safety.It has obvious improvement on nausea and vomiting symptoms and physical condition of patients undergoing chemotherapy,and is helpful to the improvement of TCM syndromes.